Digital PCR News and Research

RSS

Research highlights ability of Bio-Rad's ddPCR in quantifying minimal residual disease

More than 30 abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, December 1-4, featured research highlighting the ability of Bio-Rad's Droplet Digital PCR to provide high sensitivity and accuracy in quantifying minimal residual disease -- those remaining cancer cells after therapy that are associated with relapse -- in blood diseases such as leukemia.

3 Dec 2018

New ddPCR technology helps detect, quantify TERT promoter mutations linked to many cancer types

A recent study published online in the Journal of Molecular Diagnostics demonstrated that Droplet Digital PCR technology can be used to detect mutations in a region of our DNA that is linked to many cancer types, paving the way for the development of new cancer diagnostics and therapies.

31 Oct 2018

TGen scientists develop new quality-control assay to detect cancer from patient's blood sample

Imagine how much patients could benefit if you could discover the presence of cancer, and even how that cancer develops over time, with a simple blood test.

10 May 2018

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples.

12 Apr 2018

New blood stabilization method prolongs lifespan of blood samples for CTC profiling

A new blood stabilization method, developed at the Massachusetts General Hospital Center for Engineering in Medicine, significantly prolongs the lifespan of blood samples for microfluidic sorting and transcriptome profiling of rare circulating tumor cells (CTCs), living cancer cells carried in the bloodstream.

9 Jan 2018

Highly sensitive blood test holds potential for quickly tracking cancer growth and spread

Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.

14 Aug 2017

Cancer cells may lose copies of ribosomal DNA to enable faster proliferation, study shows

Research from the Stowers Institute provides evidence suggesting that cancer cells might streamline their genomes in order to proliferate more easily.

23 Jun 2017

MGH-developed CTC-iChip with digital PCR assay improves detection of early-stage liver cancer

Use of an advanced form of the commonly used polymerase chain reaction (PCR) method to analyze circulating tumor cells (CTCs) may greatly increase the ability to diagnose early-stage cancer, increasing the likelihood of successful treatment.

20 Jan 2017

Presence of tumor DNA in blood linked to poor outcomes in pancreatic cancer patients

The presence of circulating tumor DNA (ctDNA) isolated from blood samples of patients with pancreatic adenocarcinoma was associated with poor outcomes.

19 Dec 2016

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued.

8 Feb 2016

New test predicts breast cancer relapse months in advance

UK-based researchers have developed a blood test that can predict whether patients with breast cancer will experience a relapse after receiving treatment, months before tumors are visible using hospital scans.

27 Aug 2015

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

Kalorama Information estimated the budding market for digital PCR reached 175 million in 2014. The market research publisher said companies will be looking to provide products to increase research and diagnostics in diseases like cancer and neurological disorders.

13 Mar 2015

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals.

10 Oct 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR).

28 May 2014

Researchers demonstrate power of Droplet Digital PCR at 2014 AACR annual meeting

Helping doctors monitor their melanoma patients' progress in response to treatment is just one of the many exciting applications of Bio-Rad's Droplet Digital PCR (ddPCR-) technology being showcased at the 2014 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, CA from April 5-9.

7 Apr 2014

Massachusetts Life Sciences Center provides $1.65M in capital grant to North Shore InnoVentures

North Shore InnoVentures, one of New England's leading technology incubators and business accelerators, announced today that it has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center.

From Evident Corporation - Life Sciences 28 Mar 2014

RainDance Technologies closes $16.5 million Series E financing round

RainDance Technologies, Inc., an innovative genomics tools company making molecular testing of complex diseases more standardized and readily available, today announced that it has closed a $16.5 million Series E financing round extension. New investors include GE Ventures and Northgate Capital; all existing financial investors also participated in this round of financing.

3 Mar 2014

Scientists to highlight Bio-Rad's Droplet Digital PCR applications at CHI Digital PCR Conference

Since its introduction in 2011, Bio-Rad Laboratory's Droplet Digital PCR (ddPCR-) technology has demonstrated the potential to be a transformative technology, particularly in clinical applications.

8 Oct 2013

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

A study published today in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA deletions associated with a range of diseases and disorders as well as aging. This approach, which relies on Droplet Digital PCR (ddPCR-) technology, will help researchers explore mtDNA deletions as potential disease biomarkers.

4 Sep 2013